Naraverg (Naratriptan)

Naratriptan is a selective 5‑HT1B/1D receptor agonist used in the acute management of migraine and related headache disorders.

• Migraine: provides rapid relief of moderate to severe migraine attacks.
• Migraine with aura: alleviates headache and associated neurological symptoms.
• Acute migraine attacks in adults who require an alternative to other triptans: offers an additional therapeutic option when other agents are ineffective or not tolerated.

• Naratriptan binds selectively to serotonin 5‑HT1B and 5‑HT1D receptors on intracranial blood vessels and trigeminal nerve terminals. Activation of these receptors causes cranial vasoconstriction and inhibits the release of pro‑inflammatory neuropeptides, thereby interrupting the trigeminovascular pain pathway responsible for migraine attacks.

Common Side Effects

• Tingling or numbness in the fingers or toes.
• Flushing or warmth sensation.
• Dizziness or light‑headedness.
• Nausea or abdominal discomfort.
• Fatigue or drowsiness.
• Dry mouth.

Serious or Rare Side Effects

• Chest pain or tightness suggestive of coronary vasospasm.
• Severe hypertension.
• Serotonin syndrome, especially when combined with other serotonergic agents.
• Allergic reactions such as rash, itching, or swelling.
• Persistent visual disturbances.
• Severe abdominal pain or gastrointestinal bleeding.

Before using Naraverg, consider the following safety measures.

• Cardiovascular disease: avoid if you have uncontrolled hypertension, coronary artery disease, or a history of myocardial infarction.
• Stroke or transient ischemic attack: contraindicated in patients with a recent cerebrovascular event.
• Hemiplegic or basilar migraine: not recommended due to increased vascular risk.
• Concomitant serotonergic drugs: monitor for signs of serotonin syndrome.
• Pregnancy and lactation: discuss potential risks with a healthcare professional before use.
• Store at ambient temperature: keep below 25 °C, retain in the original container, and protect from moisture and direct sunlight.

Naratriptan may interact with several medication classes.

Major Interactions (Avoid)

• Ergot alkaloids (e.g., ergotamine): combined vasoconstriction can precipitate serious cardiovascular events.
• Monoamine oxidase inhibitors (MAOIs): increased risk of serotonin syndrome.
• Selective serotonin reuptake inhibitors (SSRIs) or serotonin‑norepinephrine reuptake inhibitors (SNRIs): heightened potential for serotonin toxicity.

Moderate Interactions (Monitor Closely)

• CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin): may raise naratriptan plasma levels.
• Antihypertensive agents: monitor blood pressure as vasoconstriction may counteract effects.
• Other triptans: avoid concurrent use to reduce cumulative vasoconstrictive risk.